G
KRTX

Gainplan’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Gainplan’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,500
Closed -$866K – 51
2019
Q4 		$866K Buy
+11,500
New +$504K 0.46% 19

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Gainplan's KRTX Position: Q1 2020 in Review

Gainplan sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2020, closing a stake of 11,500 shares — an estimated $866K sold.

Gainplan first reported a position in KRTX in Q4 2019 and held it in 1 quarter. The position peaked at $866K in Q4 2019. 99 funds tracked by Wall St. Rank hold KRTX as of Q1 2020.

  • Gainplan reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Gainplan sold 11,500 Karuna Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $866K.
  • Gainplan first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Gainplan's Karuna Therapeutics, Inc. Common Stock position peaked at $866K in Q4 2019.
  • 99 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Gainplan's 13F filing for Q1 2020, filed 11 May 2020.